The Tribunal found that Robert Stannard committed an Anti-Doping Rule Violation (ADRV) for use of a prohibited substance or a prohibited method due to unexplained abnormalities in his Biological Passport* in 2018 and 2019. These abnormalities were thoroughly followed up and investigated by the ITA after the UCI delegated its operational anti-doping program to the independent organisation in the beginning of 2021. As a consequence, the Tribunal has imposed a four-year period of suspension on the rider as well as a monetary fine corresponding to 70% of his average annual salary in 2018 and 2019.
In accordance with the applicable rules, i.e. the World Anti-Doping Code and the UCI Anti-Doping Rules, the Tribunal decided that the period of suspension shall start on 17 August 2018, i.e. the day of the appearance of the first abnormality, taking into account the delay with which the rider’s abnormalities were communicated to the UCI.
The decision is not final as it can be appealed before the Court of Arbitration for Sport (CAS) by the rider, his National Federation and National Anti-Doping Agency, the UCI and the World Anti-Doping Agency (WADA) within one month. The decision will be published on the UCI website once final.
The ITA will not comment further on the matter.
The International Testing Agency (ITA) confirms that samples it collected out-of-competition (OOC) on 27 October 2022 from Ukrainian weightlifters Ruslan Kozhakin and Bohdan Taranenko returned an Adverse Analytical Finding (AAF)[1] for the presence of the prohibited substance trimetazidine, a non-specified prohibited substance, according to the prohibited list of the World Anti-Doping Agency (WADA).
Following the results management process, the ITA submitted the matters for adjudication to the Anti-Doping Division of the Court of Arbitration for Sport (CAS ADD). On 24 May 2024, CAS ADD issued its final decision confirming that the athletes had committed Anti-Doping Rule Violations (ADRVs) and sanctioned Ruslan Kozhakin and Bohdan Taranenko each with a period of ineligibility of 48 months from 2 December 2022 and a disqualification of their competitive results from 27 October 2022 onwards. The athletes have also been granted a 6-month credit for providing Substantial Assistance[2] to the Ukrainian National Anti-Doping Organization.
Additionally, an OOC sample collected by the ITA from Alina Marushchak on 10 March 2023 returned an AAF for the presence of the prohibited substance hydrochlorothiazide, a specified prohibited substance, according to the prohibited list.
The case was resolved via an agreement on consequences pursuant to article 8.3.1 of the anti-doping rules of the International Weightlifting Federation (IWF ADR, and the equivalent provision in the World Anti-Doping Code). The athlete accepted a period of ineligibility of two years from 13 April 2023 and the disqualification of all competitive results from 10 March 2023 onwards.
Given that the three athletes from the Ukrainian Weightlifting Federation have committed ADRVs within a 12-month period, this has triggered the Article 12.3[3] of the IWF ADR and provisions of the IWF Olympic Qualification System (OQS). As a result, the matter will now be submitted to IWF’s Independent Member Federation Sanctioning Panel to impose appropriate consequences.
No further comments will be made on this case.
THE ITA, ON BEHALF OF IRONMAN, HEREBY REPORTS THAT ITALIAN ATHLETE VINCENZO TOMASELLO HAS COMMITTED AN ANTI-DOPING RULE VIOLATION (ADRV) UNDER ARTICLE 2.1 OF THE IRONMAN ANTI-DOPING RULES (IRONMAN ADR) FOR THE PRESENCE OF PREDNISOLONE AND PREDNISONE IN A SAMPLE COLLECTED IN-COMPETITION BY IRONMAN ON 25 NOVEMBER 2022 IN THE SCOPE OF THE 2022 IRONMAN ISRAEL. VINCENZO TOMASELLO PARTICIPATED IN THE EVENT IN THE AGE GROUP CATEGORY.
The sample collected from Vincenzo Tomasello returned an adverse analytical finding for the specified prohibited substances prednisolone and prednisone. Both substances are prohibited in-competition only and when administered via specific routes under the World Anti-Doping Agency’s Prohibited List as glucocorticoids (S9). Glucocorticoids are used for pain-relief and anti-inflammation.
After review of the case file, the ITA found that a fourteen (14) month period of ineligibility pursuant to article 10.6.1.1. IRONMAN ADR1 and disqualification of results from the 2022 IRONMAN Israel (25 November 2022) going forward were the applicable consequences. Mr Vincenzo accepted the consequences proposed by the ITA and the case was resolved via an acceptance of consequences pursuant to article 8.3.1 of the IRONMAN ADR. Since the athlete had accepted a voluntary provisional suspension pending the resolution of his case, the athlete’s period of ineligibility across all sports runs until 26 May 2024.
The FEI Tribunal has issued its Final Decision in a human doping case.
This case involves an adverse analytical finding for the prohibited substances listed in Class S1.1 Anabolic Androgenic Steroids, of the World Anti-Doping Agency (WADA) Prohibited List 2022.
A sample taken from the Polish Dressage athlete Katarzyna Milczarek (FEI ID 10003275) on 7 August 2022, during the FEI World Championships held in Herning (DEN), returned positive for Testosterone and metabolites. The athlete was notified of the violation of the FEI’s Anti-Doping Rules for Human Athletes (ADRHA) and provisionally suspended on 27 September 2022.
In its Final Decision, the FEI Tribunal decided to suspend the athlete for a period of 16-months, commencing from the date of the Operative Decision, for the violation of article 2.1 of the ADRHA – presence of a prohibited substance in the athlete’s sample. The Provisional Suspension already served, was credited against the imposed ineligibility period and accordingly the suspension was lifted on 26 January 2024. Additionally, all results obtained by the athlete at the FEI World Championships as well as all results obtained by the athlete as of the sample collection date until the imposition of provisional suspension were disqualified.
The parties can appeal to the Court of Arbitration for Sport (CAS) within 21 days of receipt of the decision.
The FEI Tribunal’s Final Decision is available here.
Following the launch of the sample re-analysis program for the Olympic Games Rio 2016, the ITA reports that the re-analysis of a sample collected from athlete Christos Volikakis has returned an Adverse Analytical Finding¹ for SARMS LGD-4033 metabolite, a non-specified prohibited substance according to the Prohibited List of the World Anti-Doping Agency (WADA).
The sample was collected by the IOC during an in-competition anti-doping control performed on 16 August 2016 during the cycling track sprint event at the Olympic Games Rio 2016. The sample was first analysed during the Olympic Games Rio 2016 and was reported as negative with the detection methods applied by the WADA-accredited laboratory available at the time.
The athlete has been informed of the case. He has the right to request the analysis of the B-sample. If the B-sample analysis is requested and confirms the result of the A-sample, or if the B-sample analysis is not requested, the case will proceed as a confirmed anti-doping rule violation. The athlete has the opportunity to present his explanations for the positive result.
The matter will thereafter be referred to the Anti-Doping Division of the Court of Arbitration for Sport (CAS ADD) for adjudication under the IOC Anti-Doping Rules.
Given that the case is underway, there will be no further comments during the ongoing proceeding.
UK Anti-Doping (UKAD) has issued British Triathlete Louis Walker with a three-year ban from all sport following Anti-Doping Rule Violations (ADRVs) for the Use and Possession of the Prohibited Substance, clenbuterol.
In February 2023, UKAD received intelligence via its confidential reporting initiative ‘Protect Your Sport’ that Mr Walker had been found in possession of a blister pack of Clenoxin tablets containing clenbuterol. Mr Walker admitted to both using and being in possession of clenbuterol during an interview with UKAD on 3 April 2023.
Clenbuterol is listed under Section 1.2 of the World Anti-Doping Agency (WADA) 2023 Prohibited List as an Anabolic Agent. It is a non-Specified Substance that is prohibited at all times.
Mr Walker was provisionally suspended by UKAD on 27 September 2023 and subsequently charged with Anti-Doping Rule Violations (Use and Possession of a Prohibited Substance) under the UK Anti-Doping Rules (ADR). Mr Walker responded to UKAD within 20 days of the Charge to admit both violations and accept the sanction. His early admission and acceptance of the sanction allowed his ban to be reduced by one-year.
Affording Mr Walker credit for the time he spent provisionally suspended, his ban from sport is deemed to have commenced on 27 September 2023 and will expire on 26 September 2026.
Hamish Coffey, UKAD’s Director of Operations said: “The use of anabolic agents, like clenbuterol, is cheating and undermines the hard-work and determination of clean athletes.
“This case serves as a reminder of how important it is to report your suspicions of doping. It takes a team to keep sport clean. No matter how small the information may seem, we want to hear it so we can ensure a level playing field for athletes.”
British Triathlon added, “We support UKAD’s decision and thank the person who initially raised their concerns about the athlete. As a national governing body, we are committed to clean sport and encourage anyone with a concern about an athlete to contact UKAD directly.
“Since 2021, British Triathlon has increased the education and training available to elite and amateur athletes. All Home Nation members, and any athlete and their athlete support personnel who is a member of British Triathlon’s affiliate organisations or licensees (including clubs, teams, associations and academies) are bound by the British Triathlon Anti-Doping Rules which are the UK Anti-Doping Rules.”
For more information on how to report doping, search: Protect Your Sport.
Published Friday, 12 January 2024.
As a follow-up to the ITA’s and the World Anti-Doping Agency’s (WADA) investigations on doping in the sport of weightlifting until 2018, the ITA had received WADA’s case file pertaining to “Operation Arrow”. This investigation focused on the practice of urine substitution at the point of collection. After a thorough assessment of the information and evidence the ITA decided to assert an anti-doping rule violation (ADRV) for sample swapping against athlete Nijat Rahimov (Kazakhstan). The urine substitution (Article 2.2 of the IWF Anti-Doping Rules) occurred on four occasions over a period of time in 2016, in preparation for the Olympic Games Rio 2016.
On 22 March 2022, the anti-doping division of the Court of Arbitration for Sport (CAS ADD) sanctioned the athlete with 8 years of ineligibility and the disqualification of all results obtained from 15 March 2016.
On 12 April 2022, the athlete filed an appeal before CAS. A hearing took place on 22 September 2022 at the CAS headquarters in which the ITA represented the International Weightlifting Federation (IWF). After hearing the parties and considering the written submissions and evidence, CAS confirmed that the athlete had committed several ADRVs for the of use of a prohibited method (urine substitution) in accordance with Article 2.2 of the IWF Anti-Doping Rules.
In its decision, CAS notably held that this matter was “a clear case of cheating by an athlete seeking to avoid anti-doping testing” and that “this is the kind of cheating the anti-doping rules are designed to prevent”.
Since this was the athlete’s second ADRV, CAS confirmed that Nijat Rahimov should be sanctioned with 8 years of ineligibility. The disqualification of all results obtained by the athlete from 15 March 2016 (date of the first evidence of urine substitution) until the provisional suspension imposed on 18 January 2021, which includes the gold medal obtained at the Olympic Games Rio 2016 (Men’s 77 kg), was also confirmed.
The ITA will not comment further on this case.
The FEI Tribunal has issued its Final Decision in a human anti-doping case.
This case involves an adverse analytical finding for Hydrochlorothiazide and its metabolite, Chloraminophenamide, which are included in the category of class “S5 - Diuretics and Masking Agents” according to the World Anti-Doping Agency (WADA) Prohibited List.
A sample taken from the Argentinian athlete Fabian Sejanes (FEI ID 10001261) on 11 August 2022, during the FEI World Championships held in Herning, Denmark, from 5-14 August 2022, returned positive for the Prohibited Substance mentioned above. The athlete was notified of the violation of the FEI’s Anti-Doping Rules for Human Athletes (ADRHA) on 11 October 2022.
In its Final Decision, the FEI Tribunal decided to suspend the athlete for a period of 18-months, starting from the date of the FEI Tribunal Final Decision (27 October 2023). Additionally, the athlete was disqualified from all results obtained at the event as well as all other competitive results obtained by the athlete from the date of his sample collection were disqualified. Finally, the athlete was fined CHF 3,000 and asked to pay costs of CHF 1,500.
The parties can appeal to the Court of Arbitration for Sport (CAS) within 21 days of receipt of the decision.
The full text of the FEI Tribunal’s Final Decision is available here.
THE INTERNATIONAL TESTING AGENCY (ITA) REPORTS THAT EGYPTIAN SQUASH ATHLETE MOUSTAFA ELSIRTY HAS ACCEPTED A 6-MONTH PERIOD OF INELIGIBILITY AFTER TESTING POSITIVE FOR A PROHIBITED SUBSTANCE.
The ITA confirms that a sample collected in-competition from Moustafa Elsirty on 10 November 2022 at the 2022 FISU World University Championship Squash returned an Adverse Analytical Finding (AAF) for the prohibited substance terbutaline.
Terbutaline is classified as a beta-2 agonist on the World Anti-Doping Agency’s (WADA’s) prohibited list. It is banned for athletes at all times, during and between competitions.
The case was resolved via an acceptance of consequences pursuant to Article 8.3.1. of the World Squash Federation’s anti-doping rules. The athlete accepted a sanction of a 6-month period of ineligibility from 10 March 2023 until 9 October 2023. The athlete’s individual results from 10 November 2022, including the 2022 FISU World University Championship Squash, until 10 March 2023 have also been disqualified.
The prosecution of the matter was handled by the ITA on behalf of the World Squash Federation.
Further to the World Anti-Doping Agency’s (WADA's) Executive Committee (ExCo) meeting of 22 September 2023, and the update of 28 September 2023, WADA wishes to update stakeholders regarding the ExCo’s decision to follow the recommendation of WADA’s independent Compliance Review Committee (CRC) to allege new consequences and reinstatement conditions against the Russian Anti-Doping Agency (RUSADA), which is already non-compliant with the World Anti-Doping Code(1). The non-compliance in this case was a result of a non-conformity relating to national legislation that was identified during a virtual audit in September 2022 and not addressed to date.
Under Article 9.3.1 of the International Standard for Code Compliance by Signatories (ISCCS), RUSADA had 21 days following the date of receipt of the formal notice of non-compliance to dispute the consequences and/or the reinstatement conditions proposed by the Agency.
Today, WADA has received formal notification from RUSADA that it disputes WADA’s allegation of non-compliance, the proposed consequences and reinstatement conditions. WADA will shortly refer the matter to the Court of Arbitration for Sport (CAS) for its consideration. As such, the consequences will not apply until such time as CAS makes its ruling.
(1) As it relates to the December 2020 decision by CAS, since the end of the two-year period of consequences imposed by CAS, WADA has been assessing and monitoring RUSADA to see whether it meets all the reinstatement conditions contained in the CAS decision. Until all the reinstatement conditions are met, RUSADA cannot be considered for reinstatement. In addition, RUSADA will not be eligible for reinstatement under the CAS Award until the non-conformity related to its national legislation (described above) is resolved.
For more information on non-compliant Signatories
There are currently four non-compliant Code Signatories. They are the NADOs from the Democratic People’s Republic of Korea, Gabon and Russia, as well as the International Fitness and Bodybuilding Federation.
For more information on the Signatories and the consequences, please visit the ‘Global list of non-compliant signatories and applicable consequences’ page of WADA’s website. While WADA will monitor the implementation of the consequences, under Code Article 24.1.9, other Signatories to the Code must recognize and implement the consequences in full.
The International Testing Agency (ITA), mandated by the Olympic Council of Asia (OCA) to independently handle areas of the anti-doping program at the Asian Games Hangzhou 2022, including results management, reports that a sample collected from boxing athlete Chinzorig Baatarsukh from Mongolia has returned an Adverse Analytical Finding¹ for metandienone metabolite, a non-specified Prohibited Substance, according to the Prohibited List of the World Anti-Doping Agency (WADA).
The sample was collected by the ITA at the Asian Games Hangzhou 2022 during an in-competition anti-doping control performed on 4 October 2023. The Sample Collection Authority was the China Anti-Doping Agency.
The athlete has been informed of the case. He has the right to request the analysis of the B-samples.
The matter will thereafter be referred to the Anti-Doping Division of the Court of Arbitration for Sport (CAS ADD) for adjudication under the OCA Anti-Doping Rules.
Given that the case is underway, there will be no further comments during the ongoing proceeding.
List of Anti-Doping Rule Violations at the Asian Games Hangzhou 2022
As we approach the final stages of the 2023 tour season, the ITIA is reminding players and their support teams to be aware of upcoming changes to the WADA [World Anti-Doping Agency] Prohibited List, which will take effect from 1 January 2024.
The full list of prohibited substances has been published by WADA and is available here. The most notable change to the list is the addition of tramadol, a well-known and commonly used pain-killing drug. Tramadol will become a prohibited substance in the new year, following recommendation of the List Expert Advisory Group to prohibit its use in competition from 2024.
Tramadol has been on the WADA Monitoring Program and data gathered through that programme have indicated significant use in sports. Tramadol abuse, with its dose-dependent risks of physical dependence, opiate addiction and overdoses in the general population, is of concern and has led to it being a controlled drug in many countries. Research studies funded by WADA have also confirmed the potential for tramadol to enhance sports performance.
The ITIA will work with everyone on the tennis tour to ensure that players understand the changes to the WADA Prohibited List in 2024. Players who currently use tramadol as part of their pain management regimen are urged to phase out its use as soon as possible, as its presence in a player’s system will constitute a breach of the Tennis Anti-Doping Programme (TADP) from January 2024 – except in the cases in which a player successfully applies for a Therapeutic Use Exemption (TUE), with legitimate medical grounds for use.
Committed to prioritising prevention of Anti-Doping Rule Violations (ADRVs) over punishment, the ITIA will – in collaboration with the ATP, WTA, and ITF - deliver a mixture of direct communication, education sessions and visual reminders in player-facing areas at tournaments to ensure that players are fully aware of the changes ahead of the 2024 season.
Nicole Sapstead, the ITIA’s Senior Director for Anti-Doping, said: “It is essential that all players and their representatives are aware of upcoming changes to the Prohibited List. In particular, players must note the addition of tramadol as a banned substance from next year.
“As a sport, we have a collective responsibility to ensure that the non-essential use of tramadol is eliminated before the changes to the Prohibited List take effect.
“Being unaware of changes to the list is, unfortunately, no defence against prospective sanctions, and it is incumbent upon the entire tennis family to protect players from unintentional doping violations by taking a proactive approach to rule changes.”
Players seeking further understanding of the WADA Prohibited List, or seeking practical support from the ITIA on anti-doping matters, can make contact with us directly via our app, through direct message on social media, or by filling out the contact form at itia.tennis.
The International Testing Agency (ITA), mandated by the Olympic Council of Asia (OCA) to independently handle areas of the anti-doping program at the Asian Games Hangzhou 2022, including results management, reports that a sample collected from track and field athlete Wesam Nasser A ALFARSI, from Saudi Arabia, has returned an Adverse Analytical Finding¹ for the non-specified prohibited substance darbepoetin (dEPO) according to the Prohibited List of the World Anti-Doping Agency (WADA).
The sample was collected by the ITA at the Asian Games Hangzhou 2022 during an out-of-competition anti-doping control performed on 29 September 2023.
The Sample Collection Authority was the China Anti-Doping Agency.
The athlete has been informed of the case and has been provisionally suspended with immediate effect. He has the right to request the analysis of the B-sample.
The matter will thereafter be referred to the Anti-Doping Division of the Court of Arbitration for Sport (CAS ADD) for adjudication under the OCA Anti-Doping Rules.
Given that the case is underway, there will be no further comments during the ongoing proceeding.
The FEI Tribunal has issued its Final Decision in a human anti-doping case.
A sample taken from the Brazilian athlete Pedro Stefani Marino (FEI ID 10017829) on 5 December 2021 during the CEI3* 160 Punta del Este (URU), returned positive for the Prohibited Substance Carboxy-THC. Carboxy-THC is a metabolite of THC (Cannabis) and is included in the Class “S8 Cannabinoids” of the World Anti-Doping Agency (WADA) Prohibited List 2021. The athlete was notified of the violation of the FEI’s Anti-Doping Rules for Human Athletes (ADRHA) on 2 February 2022.
In its Final Decision, the FEI Tribunal decided to suspend the athlete for a period of two years, starting from the date of the Final Decision (2 October 2023). Additionally, all competitive results of the Athlete obtained at the Event and from the date of the hearing onwards (15 May 2023) were disqualified with all the relevant consequences (forfeiture of any medals, points and prizes, etc.). Any competitive results from the conclusion of the Event up until the date of the hearing remained valid. Finally, the Athlete was imposed a fine of CHF 7,500 and ordered to pay costs of CHF 5,000.
The parties can appeal to the Court of Arbitration for Sport (CAS) within 21 days of receipt of the decision.
The full text of the FEI Tribunal’s Final Decision is available here.
Published Friday, 29 September 2023.
Polish professional boxer Kamil Sokolowski has been banned from all sport for a period of three years following Anti-Doping Rule Violations (ADRVs) for the Presence and Use of a Prohibited Substance.
On 12 November 2022, UK Anti-Doping (UKAD) collected an In-Competition urine Sample from Mr Sokolowski after his fight against Frazer Clarke at the AO Arena in Manchester. Analysis of Mr Sokolowski’s Sample returned Adverse Analytical Findings (AAFs) for the exogenous origin of testosterone and its Metabolites 5α-androstane-3α, 17β-diol (‘5αAdiol’) and 5βandrostane-3α,17β-diol (‘5βAdiol’).
Testosterone is listed under section S1.1 of the World Anti-Doping Agency (WADA) 2022 Prohibited List as an anabolic androgenic steroid. It is a non-Specified substance which, when administered exogenously, is prohibited in sport at all times.
On 21 April 2023, UKAD notified Mr Sokolowski of the AAFs and issued him with a Provisional Suspension from sport.
Mr Sokolowski responded to UKAD’s Notice on 30 April 2023 indicating that he used a supplement which he believed contained the Prohibited Substances found in his Sample.
On 26 May 2023, UKAD charged Mr Sokolowski with the commission of ADRVs for the Presence and Use of Prohibited Substances. Mr Sokolowski admitted the ADRVs and accepted the asserted period of Ineligibility. In accordance with ADR Article 10.8.1, Mr Sokolowski was able to reduce the asserted four-year period of Ineligibility to three years, after admitting the violations and accepting the asserted period of Ineligibility within twenty days of the Charge Letter.
Mr Sokolowski’s ban from all WADA Code-compliant sport commenced on 21 April 2023 and will expire at midnight on 20 April 2026.
Speaking on the case, Hamish Coffey, UKAD Director of Operations said: “Strict liability applies to all athletes under the Anti-Doping Rules. It is essential that athletes take responsibility for what goes in their body. By not following the rules, athletes put their health and careers at risk and they will face a lengthy ban from sport.”
Ombuds calls on athletes and Anti-Doping Organizations to take note of this important new resource
On behalf of the inaugural Athletes’ Anti-Doping Ombuds (Ombuds), Ms. Anna Thorstenson, the World Anti-Doping Agency (WADA) is pleased to announce the launch of the Athletes’ Anti-Doping Ombuds website, which is pertinent for Athletes covered by the World Anti-Doping Program.
This website is a secure platform that athletes can use to contact the Ombuds, a free, neutral and confidential resource for athletes with questions or concerns about anti-doping issues. The website includes:
-
a contact form to send concerns/questions directly to the Ombuds;
-
detailed answers to frequently asked questions; and
-
links to other useful material and platforms, such as WADA’s Speak Up platform that is a secure way to report doping or other activity that goes against anti-doping rules.
In March this year, Anna Thorstenson was announced as the inaugural Athletes’ Anti-Doping Ombuds. A Swedish lawyer and anti-doping specialist, Ms. Thorstenson is working independently of WADA; and, is overseeing the pilot project of the Ombuds Program, which includes development and publication of the new website.
“As the Athletes’ Anti-Doping Ombuds, my role is to provide Athletes with cost-free, neutral, impartial, and fair advice and assistance with regard to their anti-doping concerns and to ensure fair application of their rights,” says Thorstenson, who has worked in the anti-doping field since 2009. “The new website is an excellent gateway for any Athlete who may have questions or legitimate concerns about their rights or the anti-doping system more generally. I would invite all athletes and Anti-Doping Organizations to please take note of this important new website and for ADOs to share it with athletes within their jurisdiction.”
WADA Athlete Council Chair and ExCo member, Ryan Pini, said: “I am happy to see that the Athletes’ Anti-Doping Ombuds website is now up and running. The Ombuds Program is so important to the athlete community. I encourage athletes around the world to feel free to contact the Ombuds, Anna Thorstenson, directly via the site with any questions that they may have concerning the anti-doping system. The Ombuds role was established to fill the gap between Athletes and Anti-Doping Organizations and to provide Athletes with safe and confidential assistance when they feel they are unable to turn to their Anti-Doping Organization directly.”
Background
In November 2021, in line with the ‘Be Athlete Centered’ priority of WADA’s 2020-2024 Strategic Plan, WADA’s Executive Committee (ExCo) endorsed the one-year pilot project proposal for an Ombuds Program that was put forward by WADA’s Athlete Committee (now known as the Athlete Council since 1 January 2023). The Program was also supported by the Athlete community and other stakeholders as a natural follow up to the Athletes’ Anti-Doping Rights Act, developed by WADA’s Athlete Committee and published in June 2020.
The Ombuds provides athletes with cost-free, neutral, impartial, fair advice and assistance in relation to the World Anti-Doping Code and the entities that play a role within it.
The Ombuds Program has been launched in Europe but is available to athletes from around the world. The hope is to create guidelines so that Anti-Doping Organizations in other countries may setup similar programs, realizing that many athletes would choose to go local first.
You can learn more about the roles and responsibilities of the Ombuds on the Ombuds website.
Today, the World Anti-Doping Agency (WADA) is pleased to share outcomes from July’s inaugural meeting of its Athlete Advisory Group on Human Rights in Anti-Doping (Advisory Group), which is made up of members of WADA’s Athlete Council.
An Initial Human Rights Impact Assessment (IHRIA) was first proposed by WADA’s Athlete Committee in 2021 (now known as the Athlete Council) with the objective of ensuring that WADA respects and protects the universally recognized human rights of athletes as it leads a global collaborative mission for doping-free sport.
In November 2022, WADA’s Executive Committee (ExCo) confirmed the appointment of Senior Independent Expert, Ms. Snežana Samardžić-Marković, to lead an IHRIA to evaluate the intersection between the World Anti-Doping Program (Program) and the human rights of athletes; and, in March 2023, WADA announced that it had begun the work.
In July, the Advisory Group held its first meeting, which focused on several topics connected to the IHRIA, including:
-
Gaining a deeper understanding of the United Nations Guiding Principles (UNGP) on Business and Human Rights, which serve as the benchmark for the IHRIA;
-
Sharing personal experiences or knowledge through stories that illustrated the situations where individual human rights were tested;
-
Discussing ways to solve important strategic dilemmas, to identify and prioritize potential human rights infringements; and
-
Emphasizing communication as one of the essential aspects of the Group's efforts.
Ms. Samardžić-Marković said: "I am delighted that the Athlete Advisory Group on Human Rights in Anti-Doping convened and that we had valuable discussions about the UNGPs on Business and Human Rights. The personal stories shared during the meeting shed light on potential adverse impacts on athletes' human rights, reinforcing the importance of our work.
“In our discussions, we also addressed the Advisory Group's role in the Initial Human Rights Impact Assessment process and the strategic challenges that lie ahead. I am impressed by the dedication and expertise of the Group members, and I feel assured of their strong commitment to human rights and their support for the ongoing assessment. Together, we are taking significant steps to ensure that human rights remain a priority in anti-doping, and I look forward to continuing this essential work with the guidance and support of this remarkable group."
Athlete Council Chair and ExCo member, Ryan Pini, said: “The first meeting of the Athlete Advisory Group on Human Rights in Anti-Doping resulted in thoughtful, meaningful and productive discussions that have laid the foundation for the Group’s future successes. The Group's examination of various aspects of the anti-doping system such as public disclosure, strict liability of athletes and the professionalization of the fight against doping in sport has led to important insights. This first meeting highlighted the necessity to focus on discussing human rights in the context of anti-doping efforts, which we intend on doing in the months and years to come.
“As a new body resulting from governance reform, WADA’s Athlete Council holds a special responsibility to address the challenges identified by the Athlete Advisory Group on Human Rights in Anti-Doping. We have high expectations for what this Group of representatives can achieve for athletes around the world, and we will strive to enhance athletes' involvement and ensure their voices are heard in shaping anti-doping policy.”
The next meeting of the Advisory Group is scheduled to take place in September 2023, which will particularly focus on the most salient activities at risk to cause or contribute to adverse human rights impact. The Group will also discuss initial recommendations on how to prevent or mitigate these risks.
The International Testing Agency (ITA) confirms as follows:
- A sample collected in-competition (IC) by the ITA from Turkish weightlifter Hakan Sukru Kurnaz returned an Adverse Analytical Finding (AAF)[1] for the presence of methasterone metabolite, a non-specified prohibited substance, according to the prohibited list of the World Anti-Doping Agency (WADA). The athlete was able to establish that the presence of methasterone metabolite in his sample was through use of a contaminated supplement. The case was resolved via an agreement on consequences pursuant to article 8.3.1 of the anti-doping rules of the International Weightlifting Federation (IWF ADR, and the equivalent provision in the World Anti-Doping Code). The athlete accepted a period of ineligibility of 22 months from 26 May 2023 and the disqualification of all competitive results from 21 April 2023 onwards.
- A sample collected IC by the ITA from Turkish weightlifter Pelinsu Bayav returned AAFs for the presence of methasterone, stanozolol metabolites, methyltestosterone metabolite and clenbuterol, non-specified prohibited substances, according to the prohibited list of WADA. The athlete admitted to the violation under Article 10.8.1 IWF ADR and the case was resolved via an agreement on consequences pursuant to article 8.3.1 IWF ADR. The athlete accepted a period of ineligibility of 36 months from 26 May 2023 and the disqualification of all competitive results from 15 April 2023 onwards.
- Turkish weightlifter Dogan Donen has committed an anti-doping rule violation under article 2.4 of the IWF ADR namely the occurrence of three Whereabouts Failures within a 12-month period.[2] The athlete accepted the consequences of the violation, and the ITA issued a sanctioning decision under Article 8.3.3 of the IWF ADR imposing a period of ineligibility of 24 months from 8 April 2024 and the disqualification of all competitive results from 1 April 2023 onwards.
Given that three athletes from the Turkish Weightlifting Federation have committed anti-doping rule violations (ADRVs) within a 12-month period, this has triggered the Article 12.3[3] of the IWF ADR and provisions of the IWF Olympic Qualification System (OQS). As a result, the matter has been submitted to IWF’s Independent Member Federation Sanctioning Panel to impose appropriate consequences.
No further comments will be made on these cases.
The Tribunal found Miguel Ángel López guilty of an anti-doping rule violation (ADRV) for use and possession of a prohibited substance (Menotropin)*, concomitantly with the 2022 Giro d’Italia, and has imposed a four-year suspension on the rider.
In accordance with the World Anti-Doping Code and the UCI Anti-Doping Rules, the period of suspension started on 25 July 2023 and will remain in force until 24 July 2027.
The disciplinary proceeding was initiated following an investigation conducted by the ITA based on evidence obtained from the Spanish Guardia Civil and the Spanish Anti-Doping Organisation (CELAD) in the so-called Operation “Ilex” concerning Dr Marcos Maynar. This valuable collaboration demonstrates the importance of intelligence-sharing between the ITA, National Anti-Doping Organisations and law enforcement authorities.
In line with the Procedural Rules of the UCI Tribunal, the decision will be published on the UCI website. The decision may be appealed before the Court of Arbitration for Sport (CAS) within one month.
The ITA will not comment further on the matter.
As a reminder, the UCI delegated the operational activities of its anti-doping programme to the International Testing Agency (ITA) in January 2021. Since then, cycling’s clean sport efforts have been led by the ITA Cycling Unit, which is dedicated specifically to all disciplines of cycling. The UCI and the ITA are bound by a service agreement which guarantees that the ITA operates in an independent manner.
Please find the UCI statement on the matter here.
The World Anti-Doping Agency (WADA) is pleased to publish Guidelines for Implementing the Technical Document for Sport Specific Analysis (TDSSA Guidelines) that support version 9.0 of the TDSSA.
The TDSSA is a mandatory Level 2 document that must be implemented by all Anti-Doping Organizations (ADOs) that are Signatories to the World Anti-Doping Code. These new TDSSA Guidelines replace the TDSSA Supporting Document A - Frequently Asked Questions (FAQs) and will assist ADOs in implementing the TDSSA requirements, giving practical examples and suggestions.
ADOs can find information on the analysis capacity per WADA-accredited laboratory for the Prohibited Substances within the scope of the TDSSA on WADA’s website. For Prohibited Substances outside the scope of the TDSSA, ADOs can also find the full list of specific methods that are not included in the standard sample analysis menu and are available in WADA-accredited laboratories on WADA’s website.
Application for Flexibility
ADOs are also reminded that in accordance with Article 4.7.2 of the International Standard for Testing and Investigations, ‘an ADO may apply to WADA for flexibility in the implementation of the MLA specified for Prohibited Substances or Prohibited Methods as outlined in the TDSSA’. ADOs can apply for flexibility (up to 50%) in the implementation of the MLAs against set criteria listed in Articles 3 and 6 of the TDSSA.
TDSSA Testing Guides
Finally, information on the Prohibited Substances and Methods within the scope of the TDSSA and guidance on Testing strategies for each Prohibited Substance is provided within the TDSSA Testing Guides. A Testing Guide on Gas Chromatography/Combustion/Isotope Ratio Mass Spectrometry (GC/C/IRMS) is also available. ADO staff involved in test planning and target testing of athletes are advised to be familiar with these Testing Guides, which can be requested by contacting WADA at This email address is being protected from spambots. You need JavaScript enabled to view it..
Should you have any questions or comments regarding the TDSSA Guidelines, the TDSSA Testing Guides, or the application for flexibility, we invite you to contact This email address is being protected from spambots. You need JavaScript enabled to view it..
The Court of Arbitration for Sport (CAS) has dismissed the appeal filed by Italian racewalker Alex Schwazer against the decision taken by the Athletics Integrity Unit (AIU) of World Athletics (WA) on 10 November 2023 (the Challenged Decision) in which his application, pursuant to Rule 10.7.1 (a) of the World Athletics Anti-Doping Rules (WA ADR), to suspend the eightyear period of ineligibility,starting from 11 August 2016, imposed on him for hissecond doping offence was rejected.
WA denied the Athlete’s “Substantial Assistance Application” following the negative assessment issued by the World Anti-doping Agency (WADA) in relation to this matter.
The Challenged Decision is confirmed, and the period of ineligibility imposed on Alex Schwazer remains in force.
Rule 10.7.1 (a) of the WA ADR enables athletes serving a period of ineligibility to apply for the suspension of part of such period upon provision of substantial assistance in discovering or establishing other anti-doping rule violations.
The CAS Panel has issued the operative part of its decision. The reasoned award will be notified to the parties in due course and published by CAS unless the parties request confidentiality.
The International Tennis Integrity Agency (ITIA) can today confirm that an agreement has been reached with American player Jenson Brooksby, which sees their period of ineligibility reduced to 13 months.
In October 2023, Brooksby - who reached a career-high world singles ranking of 33 in 2022 - was issued an 18-month suspension by an independent tribunal for missing three anti-doping tests in a 12-month period. However, new information relating to the circumstances giving rise to the missed tests - which had not previously been available to the ITIA or the independent tribunal during the initial hearing - was submitted as part of the player’s Court of Arbitration for Sport (CAS) appeal proceedings.
On the basis of a detailed review of the new information, the ITIA, in consultation with the World Anti-Doping Agency (WADA), determined that the player’s degree of fault for the Anti-Doping Rule Violation (ADRV) should be reassessed.
Following reassessment, the ITIA, WADA, and the player’s representatives agreed that Brooksby’s fault for the ADRV was not as high as previously found by the independent tribunal, and a 13-month sanction was appropriate. The sanction will be backdated to the date of the player’s third and final missed test. As such, Brooksby’s suspension is deemed to have begun on 4 February 2023, and will end on 3 March 2024. In reaching an agreement with the ITIA, the player has withdrawn their appeal to CAS.
Due to the nature of the new information disclosed, it is not possible for the ITIA to discuss the specific details behind the reassessment or offer further comment.
USADA announced today that Frank Travieso, of Athens, Ga., an athlete in the sport of cycling, has accepted a six-month period of ineligibility for an anti-doping rule violation after testing positive for a prohibited substance.
Travieso, 43, tested positive for ephedrine at a concentration greater than the threshold of 10 micrograms per milliliter as the result of a urine sample collected at the Bommarito Audi Gateway Cup on September 3, 2023. Ephedrine is a Specified Substance in the class of Stimulants and is prohibited in-competition under the USADA Protocol for Olympic and Paralympic Movement Testing, the United States Olympic Committee National Anti-Doping Policies, and International Cycling Union (UCI) Anti-Doping Rules, all of which have adopted the World Anti-Doping Code and the World Anti-Doping Agency (WADA) Prohibited List.
After investigating, USADA determined that Travieso was using a medication containing ephedrine, which he obtained over the counter at the direction of a physician, but he lacked a valid Therapeutic Use Exemption (TUE). Under the USADA TUE Policy, an athlete has the responsibility to demonstrate that the therapeutic need to treat an acute or chronic medical condition satisfies the strict criteria within the WADA International Standard for TUEs (ISTUE). Upon review, Travieso did not qualify for a retroactive TUE.
Travieso’s six-month period of ineligibility began on September 21, 2023, the date his provisional suspension was imposed. In addition, Travieso has been disqualified from all competitive results obtained on and subsequent to September 3, 2023, the date his positive sample was collected, including forfeiture of any medals, points and prizes.
USADA announced today that Tyler Sundeen, of Simi Valley, Calif., an athlete in the sport of field hockey, has accepted a six-month sanction for an anti-doping rule violation.
Sundeen, 30, tested positive for ritalinic acid, a methylphenidate metabolite, as the result of an in-competition sample collected at the Cal Cup Tournament on May 27, 2023. He also declared the use of this substance during sample collection. Methylphenidate is a Specified Substance in the class of stimulants and is prohibited in-competition under the USADA Protocol for Olympic and Paralympic Movement Testing, the United States Olympic and Paralympic Committee National Anti-Doping Policies, and the International Hockey Federation Anti-Doping Rules, all of which have adopted the World Anti-Doping Code and the World Anti-Doping Agency (WADA) Prohibited List.
After investigating, USADA determined that Sundeen was taking methylphenidate at the direction of a physician but lacked a valid Therapeutic Use Exemption (TUE). Under the USADA TUE Policy, an athlete has the responsibility to demonstrate that the therapeutic need to treat an acute or chronic medical condition satisfies the strict criteria within the WADA International Standard for TUEs (ISTUE). Although the substance was taken at the direction of a physician, Sundeen lacked a valid Therapeutic Use Exemption (TUE) and his subsequent application for a retroactive and prospective TUE, reviewed by the independent USADA TUE Committee of expert physicians, was denied due to lack of sufficient medical justification. Under the applicable rules, Sundeen was eligible for a reduction from the default period of ineligibility based on the specific circumstances of his case.
Sundeen’s six-month period of ineligibility began on June 16, 2023, the date his provisional suspension was imposed. Sundeen has been disqualified from all competitive results obtained on and subsequent to May 27, 2023 including forfeiture of any medals, points, and prizes.
In an effort to aid athletes, as well as support team members such as parents and coaches, in understanding the rules applicable to them, USADA provides comprehensive instruction on its website on the testing process and prohibited substances, how to file and update athlete Whereabouts, how to obtain permission to use a necessary medication, and the risks and dangers of taking supplements, as well as performance-enhancing and recreational drugs.
In addition, USADA manages a drug reference hotline, Global Drug Reference Online (GlobalDRO.com), conducts educational sessions with National Governing Bodies and their athletes, and distributes a multitude of educational materials, such as a supplement guide, a nutrition guide, a clean sport handbook, and periodic alerts and advisories.
USADA makes available a number of ways to report the abuse of performance-enhancing drugs in sport in an effort to protect clean athletes and promote clean competition. Any tip can be reported using the USADA Play Clean Tip Center, by text at 87232 (“USADA”), by email at This email address is being protected from spambots. You need JavaScript enabled to view it., by phone at 1-877-Play Clean (1-877-752-9253) or by mail.
USADA is responsible for the testing and results management process for athletes in the U.S. Olympic and Paralympic Movement and is equally dedicated to preserving the integrity of sport through research initiatives and educational programs.
The Athletics Integrity Unit (AIU) was pleased to collaborate with the World Anti-Doping Agency (WADA) to host an Anti-Doping Intelligence and Investigations Network (ADIIN) Expert Group session in Monaco last week.
The seventh annual session, which ran from 25-26 October, welcomed around 25 participants from WADA Intelligence & Investigations (I&I), National Anti-Doping Organizations (NADOs), International Federations and the International Testing Agency to discuss ongoing investigations and share their respective experiences.
WADA Director, Intelligence and Investigations, Gunter Younger, said: “This week’s session in Monaco was an excellent opportunity for intelligence and investigations practitioners to get together and share experiences and reflect on how to further strengthen the anti-doping process from an intelligence and investigations perspective. We are very grateful to our colleagues from the Athletics Integrity Unit for hosting the event and for their strong commitment to this important area. Through collaboration like this we are improving the overall system for athletes and clean sport around the world.”
Head of the Athletics Integrity Unit, Brett Clothier, said: “The AIU has been a central member of the ADIIN group since our inception, so it was a pleasure to welcome its members to Monaco for the annual in-person meeting. Investigations and intelligence are at the heart of good anti-doping work and ADIIN is therefore an expert group with an important role. The last two days have furthered the consideration of I&I’s role in the future of anti-doping.”
In particular during this interactive session, the members examined two key provisions of the World Anti-Doping Code (Code), namely Article 10.7.1 (Substantial Assistance) and Article 10.8.1 (Early Admission and Acceptance of Sanction) and discussed how they could better reflect the operational needs and constraints of I&I practitioners. To complement these discussions on I&I challenges and opportunities, the group also heard from General Counsel, United States AntiDoping Agency, Jeff Cook, who offered insight into how the Code and the International Standard for Results Management intersected with criminal prosecutions.
The outcomes of the meeting will be reviewed by the ADIIN steering committee and shared with the relevant drafting teams for the 2027 Code and International Standards Update Process, which got underway last month.
About the Anti-Doping Intelligence and Investigations Network
In 2017, to further harmonize and strengthen the investigation of doping in sport worldwide, WADA I&I started building ADIIN to serve as a global resource to assist Anti-Doping Organizations in conducting investigations, and to identify and promote best-practice investigative standards.
The World Anti-Doping Agency (WADA) has recently released the 2024 Prohibited List (the List), which details the substances and methods that are banned within sport. Broken down into several categories, the List identifies which substances and methods are prohibited at all times, in-competition only, and within specific sports.
Following an extensive consultation period by WADA, the 2024 List was published on 27 September 2023. This gives athletes and their support personnel sufficient time to make themselves aware of the changes, review any medications they use, and apply for a Therapeutic Use Exemption (TUE) if required before the updated List comes into effect on 01 January 2024.
The below sections summarise the major changes to the List for 2024. Please consult the 2024 Summary of Major Modifications and Explanatory Notes document for the full list of modifications.
Tramadol
Tramadol will be prohibited in-competition under Section 7 Narcotics.
UKAD will shortly be releasing a position statement for athletes and doctors on how to comply with the new tramadol regulations. This document will include the timeframes for when an athlete should submit a TUE for the use of tramadol, the factors to consider when making such an application, and scenarios whereby a TUE is unlikely to be granted.
Removal of plasmapheresis as a prohibited method
The donation of plasma or plasma components by plasmapheresis will no longer be prohibited when performed in a registered collection centre.
Tramazoline
Tramazoline has been added to Section 6 Stimulants as an example of an imidazoline derivative which is permitted when administered by dermatological, nasal, ophthalmic, or otic routes. It is prohibited by any other route of administration.
Additional Examples
Several new examples of prohibited substances have been added to various categories of the List. Please note that these are not new substances being added to the 2024 List for the first time but are additional examples of substances that are already prohibited.
Monitoring Program
WADA has also published the 2024 Monitoring Program which lists substances (not on the Prohibited List) that are currently being monitored for potential misuse by WADA.
The World Anti-Doping Agency (WADA) is pleased to share its plan to promote clean sport during the 2023 Pan American (Panam) and Parapan American (Parapan Am) Games in Santiago, Chile.
WADA will have its Athlete Engagement and Independent Observer (IO) teams on site for the Panam Games, which will run from 20 October until 5 November. The Athlete Engagement team will then stay through the Parapan Games, which will take place between 17-26 November. Together, both events will feature more than 8,000 athletes from 41 countries, which will compete across 39 sports in the Panam Games and 17 in the Parapan Games.
WADA’s IO program is designed to enhance athlete and public confidence as to the quality, effectiveness, and reliability of anti-doping programs during major international multisport events. WADA’s Athlete Engagement initiatives are in place to raise awareness about doping-free sport among athletes and their support personnel while also promoting clean sport.
WADA President, Witold Bańka, said: “We look forward to running our Athlete Engagement and Independent Observer programs in Santiago. The Independent Observer team will collaborate with our partners on the ground to help strengthen the anti-doping program during the Panam Games. Meanwhile, our Athlete Engagement team will have the important task of engaging with athletes at both the Panam and Parapan Am Games, and their entourages, on a variety of anti-doping topics. These Games represent an important opportunity for WADA to continue to champion its global collaborative mission for doping-free sport in South America and raise the game for athletes around the world.”
Independent Observer (IO) Program
WADA will be running an IO program during the Panam Games in Santiago 2023. The anti-doping program will be operated by Panam Sports in conjunction with the local organizing committee. WADA’s IO team will collaborate with the various organizations to help strengthen the program.
Providing daily feedback to the organizers, the IO team will observe all aspects of the Games’ anti-doping program, including:
-
Test distribution planning and implementation;
-
Recruitment and training of sample collection personnel;
-
Athlete selection, notification and sample collection procedures;
-
Transport and chain of custody of samples;
-
Therapeutic Use Exemption procedures; and
-
Results management.
Following the Panam Games, the IO team will issue a report that will formalize observations and recommendations designed to enhance anti-doping activities for future events.
The IO team consists of:
-
Juan Lauria (Argentina), Manager, WADA Latin America Office (Chair);
-
Federico Perroni (Uruguay) Manager, WADA Latin America Office;
-
Maria Fernanda Carraca de Alcantara Frias (Brazil), Testing Manager, Autoridade Brasileira de Controle de Dopagem (ABCD); and
-
Clare Egan (USA), WADA Athlete Council member, International Biathlon Union Athlete Commission Chair and two-time Olympic biathlete.
In keeping with the ‘Be Athlete Centered’ priority of WADA’s 2020-2024 Strategic Plan, the Agency is ensuring that athletes are involved in all aspects of anti-doping, including being part of its IO teams. As noted above, WADA Athlete Council member Clare Egan will be on hand as part of the team to provide an athlete’s perspective throughout the monitoring process.
Clare Egan said: “I am pleased to be joining the Independent Observer team for the 2023 Pan American Games. Having members of WADA’s Athlete Council on IO teams at major events provides opportunities for the Council to assess all aspects of the anti-doping process and eventually provide feedback regarding what we can do to make this part of an athlete’s career a positive experience. It is very important to me that a robust anti-doping program is implemented while still respecting athletes’ rights."
Athlete Engagement
WADA will have an Athlete Engagement team present at both the Pan Am and Parapan Am Games to deliver the ‘One Play True Team’ campaign while raising awareness and promoting clean sport. The team will run the program jointly with the Chilean NADO. The Program also includes a legacy aspect thanks to the banners and promotional resources that will be left behind for the Chilean NADO to use for their own engagement and outreach activities at future events.
The athlete-led team includes:
-
Paola Mautino (Perú), two-time Pan American Games participant, nine-time national long jump champion and sprinter;
-
Macarena Mondaca (Chile), Manager, Education and Awareness, Chile NADO;
-
Gabriela Traña (Costa Rica), two-time Pan American Games participant, two-time Olympic long-distance runner and Costa Rican flag bearer at the 2012 London Games;
-
Stacy Spletzer-Jegen (USA), WADA Senior Manager, Athlete Engagement; and
-
Edna Serra (Uruguay), Office Manager, WADA Latin America Office.
As part of a circulatory vote that ended yesterday, the World Anti-Doping Agency’s (WADA’s) Executive Committee (ExCo) approved a revised recommendation of the Agency’s independent Compliance Review Committee (CRC) to add the Bermuda National Anti-Doping Organization (Bermuda NADO) to WADA’s compliance ‘watchlist’1.
On 22 September 2023, the ExCo followed the CRC’s recommendation to allege the Bermuda NADO as non-compliant with the World Anti-Doping Code (Code) due to a failure to appropriately implement the Code into their legislation.
In the days following the ExCo, the Bermuda NADO provided draft amendments to the legislation that WADA confirmed were in line with the Code, as well as a clear calendar for adoption of those amendments within four months. On this basis, the CRC has updated its recommendation for inclusion on the ‘watchlist’. As per the International Standard for Code Compliance by Signatories (ISCCS), by adding the Bermuda NADO to the ‘watchlist’, the ExCo has given it four months to execute its corrective action plans. If by 12 February 2024 the non-conformities have not been corrected to the satisfaction of the CRC, the Bermuda NADO will be alleged as non-compliant without the need for a further decision by the ExCo.
The CRC is responsible for providing independent advice, guidance and recommendations to WADA Management and governing bodies on matters relating to Signatories' compliance with their obligations under the Code. The CRC Chair, Mr. Henry Gourdji, will report to the next meetings of the ExCo and Foundation Board that will be held on 16 and 17 November 2023.
The International Testing Agency (ITA), mandated by the Olympic Council of Asia (OCA) to independently handle areas of the anti-doping program at the Asian Games Hangzhou 2022, including results management, reports that a sample collected from kabbadi athlete Adil Hussain from Pakistan has returned an Adverse Analytical Finding¹ for 19-norandrosterone, a non-specified Prohibited Substance, according to the Prohibited List of the World Anti-Doping Agency (WADA).
The sample was collected by the ITA at the Asian Games Hangzhou 2022 during an in-competition anti-doping control performed on 4 October 2023. The Sample Collection Authority was the China Anti-Doping Agency.
The athlete has been informed of the case. He has the right to request the analysis of the B-samples.
The matter will thereafter be referred to the Anti-Doping Division of the Court of Arbitration for Sport (CAS ADD) for adjudication under the OCA Anti-Doping Rules.
Given that the case is underway, there will be no further comments during the ongoing proceeding.
List of Anti-Doping Rule Violations at the Asian Games Hangzhou 2022
The International Testing Agency (ITA), mandated by the Olympic Council of Asia (OCA)to independently handle areas of the anti-doping program at the Asian Games Hangzhou 2022, including results management, reports that a sample collected from weightlifter Erdenezul Buyandelger, from Mongolia, has returned an Adverse Analytical Finding¹ for the non-specified prohibited steroid drostanolone metabolite according to the Prohibited List of the World Anti-Doping Agency (WADA).
The sample was collected by the ITA at the Asian Games Hangzhou 2022 during an out-of-competition anti-doping control performed on 1 October 2023. The Sample Collection Authority was the China Anti-Doping Agency.
The athlete has been informed of the case and has been provisionally suspended with immediate effect. She has the right to request the analysis of the B-sample.
The matter will thereafter be referred to the Anti-Doping Division of the Court of Arbitration for Sport (CAS ADD) for adjudication under the OCA Anti-Doping Rules.
Given that the case is underway, there will be no further comments during the ongoing proceeding.
The International Testing Agency (ITA), mandated by the Olympic Council of Asia (OCA) to independently handle areas of the anti-doping program at the Asian Games Hangzhou 2022, including results management, reports that a sample collected from Kurash athlete Tejen Tejenov from Turkmenistan, has returned an Adverse Analytical Finding¹ for the non-specified prohibited substances dehydrochloromethyl-testosterone metabolite and methasterone metabolites according to the Prohibited List of the World Anti-Doping Agency (WADA).
The sample was collected by the ITA at the Asian Games Hangzhou 2022 during an in-competition anti-doping control performed on 30 September 2023 during the Kurash Mens +90kg finals. The Sample Collection Authority was the China Anti-Doping Agency.
The athlete has been informed of the case and has been provisionally suspended with immediate effect. He has the right to request the analysis of the B-sample.
The matter will thereafter be referred to the Anti-Doping Division of the Court of Arbitration for Sport (CAS ADD) for adjudication under the OCA Anti-Doping Rules.
Given that the case is underway, there will be no further comments during the ongoing proceeding.
Today, the World Anti-Doping Agency (WADA) has signed a four-year memorandum of understanding (MOU) with the World Health Organization (WHO), which will allow experts from both international organizations to collaborate and share information on issues where anti-doping and public health intersect.
The MOU was signed in Geneva, Switzerland, by WADA President, Witold Bańka, and Director General of the World Health Organization, Dr. Tedros Adhanom Ghebreyesus. The agreement will run until 1 October 2027 and provides a framework of cooperation between WADA and WHO to further their goals, specifically with regards to health promotion, the prevention of substance abuse and emerging drugs, and the promotion of clean sport.
Mr. Bańka said: “The memorandum of understanding signed today with the World Health Organization is a watershed moment that will benefit anti-doping efforts worldwide. WADA leads the global collaborative mission for doping-free sport; and, in so doing, we also protect the health of individuals around the world. One of the three criteria for a substance to be added to WADA’s Prohibited List of Substances and Methods is if it represents an actual or potential health risk to athletes. Through our agreement with WHO, experts from both organizations will be able to work collaboratively to exchange information on emerging substances and reinforce scientific positions that will ultimately benefit not only athletes, but society as a whole.
“WHO’s commitment to health and well-being of society at large fits perfectly with our mission. I want to thank Dr. Tedros and his team at WHO for their efforts leading up to this historic agreement and for their commitment to healthy, clean sport around the globe.”
The themes of the MOU include:
-
Prevention and assessment of health risks associated with psychoactive substance use and related disorders, with a focus on doping compounds and substance use among athletes;
-
Awareness raising and advocacy for clean sport and substance misuse prevention worldwide;
-
Raising awareness through education initiatives with the support of goodwill ambassadors and influencers to drive positive change;
-
Collaboration on sub-standard and falsified medical products, including identification of new emerging psychoactive drugs through sharing of information, mutual support, and engagement with sport federations; and
-
Reporting on abuse and misuse of falsified and sub-standard medical products in sport.
Dr. Tedros said partnering with WADA reflected WHO’s commitment to work closely with the sport sector to encourage increased physical activity globally in order to promote healthier lives for all.
He said: "Sport and all forms of physical activity are essential to good health, and competitive sport plays a key role in inspiring people to be more active. The use of performance-enhancing substances can harm athletes, and certainly harms sport and those who look up to athletes as role-models. Keeping sport clean, therefore, has benefits beyond the sporting arena for the health and well-being of individuals and societies everywhere."
The MOU also aligns with the organizations’ common objective of achieving the United Nations Sustainable Goal 3: Ensuring healthy lives and promoting well-being for all at all ages. These goals stem from the United Nations’ 2030 Agenda for Sustainable Development, which was adopted by all United Nations Member States in 2015 and provides a shared blueprint for peace and prosperity for people and the planet, now and into the future.
This formal agreement between WADA and WHO follows an initial meeting between the two organizations which took place in April 2023 at the WHO headquarters in Geneva.
Today, the World Anti-Doping Agency (WADA) publishes the 2024 List of Prohibited Substances and Methods (List), which was approved by WADA’s Executive Committee (ExCo) during its meeting on 22 September 2023 and enters into force on 1 January 2024.
We also publish:
The List is one of the eight International Standards that are mandatory for all Signatories of the World Anti-Doping Code (Code). It designates what substances and methods are prohibited both in- and out-of-competition and which substances are banned in particular sports.
WADA Director General Olivier Niggli said: “We encourage athletes, their entourage and all stakeholders to acquaint themselves with the Summary of Major Modifications to avoid inadvertent use of substances and methods that are prohibited in sport for 2024. In particular, we kindly ask all Anti-Doping Organizations around the world to share the List and its related documents with athletes, their entourage and other relevant stakeholders under their jurisdiction.
Major modifications for 2024
All Major Modifications for 2024 are outlined in the 2024 Summary of Major Modifications and Explanatory Notes, including the following particular information regarding tramadol:
On 23 September 2022, the ExCo endorsed the recommendation by WADA’s List Expert Advisory Group to prohibit the narcotic tramadol in competition, effective 1 January 2024. The delay in implementation was to provide an additional year to allow enough time for stakeholders to learn and adapt to this change.
Tramadol has been on WADA’s Monitoring Program and data gathered through that program have indicated significant use in sports. Tramadol abuse, with its risk of physical dependence, opiate use disorder and overdoses, is of concern worldwide and has led to it being a controlled drug in many countries. Research studies funded by WADA, as referenced in the Explanatory Note, have also confirmed the potential for tramadol to enhance sports performance.
Annual list review process
WADA leads an annual revision process concerning the List, beginning with an initial meeting in January and concluding with the publication of the List by 1 October. This is an extensive consultation process that includes WADA’s List Expert Advisory Group gathering information including the latest scientific and medical research, trends, and intelligence gathered from law enforcement and pharmaceutical companies; circulating a draft List among stakeholders; and, taking their submissions into consideration to revise the draft, followed by review by the Agency’s Health, Medical and Research (HMR) Committee. The HMR Committee then makes its recommendations to WADA’s ExCo, which approves the List during its September meeting.
For a substance or method to be added to the List, it must be determined that it meets at least two of the following three criteria:
- It has the potential to enhance or enhances sport performance
- It represents an actual or potential health risk to the athletes
- It violates the spirit of sport
The List is released three months ahead of it taking effect so that athletes, their entourage and other stakeholders can acquaint themselves with any modifications. Ultimately, athletes are responsible for prohibited substances found in their body and prohibited methods found to have been used. Athlete entourage are also liable for Anti-Doping Rule Violations if determined to be complicit. Consequently, if there is any doubt as to the status of a substance or method, it is important that they contact their respective Anti-Doping Organizations (International Federation or National Anti-Doping Organization) for advice.
The Therapeutic use Exemption Program
It should be noted that for athletes who have a legitimate medical reason for using a prohibited substance or method that is on the List, they can apply for a Therapeutic Use Exemption (TUE) to determine whether they meet the criteria outlined in the International Standard for Therapeutic Use Exemptions (ISTUE). The TUE Program is a rigorous and necessary part of elite sport which has overwhelming acceptance from athletes, physicians and anti-doping stakeholders.
Educational Resources
In addition to the documents linked above, WADA has provided, or will provide, a number of educational resources as part of its Code Implementation Support Program (CISP), which can be accessed on the Agency’s Anti-Doping Education and Learning Platform (ADEL). These resources include:
- A CISP Checklist – Implementing Revised List (available now)
- Athlete and Athlete Support Personnel (ASP) Factsheet on tramadol (to be available in November)
- Medical Professionals Factsheet on tramadol (to be available in November)
- Athlete and ASP Guide to the 2024 List (to be available in January 2024)
Languages and Formats
The 2024 Prohibited List; the 2024 Summary of Modifications and Explanatory Notes; and the 2024 Monitoring Program are available for download on WADA’s website in English and French with Spanish to follow in the coming weeks.
Stakeholders wishing to translate the List into other languages are kindly asked to signal their interest to This email address is being protected from spambots. You need JavaScript enabled to view it.. WADA will then provide the necessary files and, once the translation is finalized, will make the translated List available on the Agency’s website.
The List’s mobile-friendly digital edition will go live on 1 January 2024.
The Court of Arbitration for Sport (CAS) confirms the following arrangements for the hearing in the arbitration procedures CAS 2023/A/9451 Association Russian AntiDoping Agency (RUSADA) v. Kamila Valieva, CAS 2023/A/9455 International Skating Union (ISU) v. Kamila Valieva, Association Russian Anti-Doping Agency (RUSADA), and CAS 2023/A/9456 World Anti-Doping Agency (WADA) v. Association Russian Anti-Doping Agency (RUSADA) & Kamila Valieva):
The hearing will take place on 26, 27 and 28 September 2023, with 29 September 2023 being a reserve day. It will be held at the CAS Headquarters in Lausanne, Switzerland, although the Panel will hear some parties, witnesses and experts via video-conference, including Ms Kamila Valieva and the representatives of RUSADA.
The parties to the proceedings: RUSADA, the ISU, WADA and Ms Valieva (collectively, the parties), want privacy and have not requested that a public hearing be held. Consequently, the hearing will take place behind closed doors in accordance with the provisions of Article 57 of the Code of Sports-related Arbitration (the “CAS Code”), and outside persons will not be authorised to attend. For that reason, on 5 September 2023, the CAS Panel denied a request filed by the 2022 United States Olympic Figure Skating Team for an observer to be permitted to attend the hearing on their behalf.
The Panel of CAS arbitrators constituted to decide the matter is composed of:
President: Mr James Drake KC, Barrister, United Kingdom & Australia
Arbitrators: Mr Jeffrey Mishkin, Attorney-at-Law, USA
Dr Mathieu Maisonneuve, Professor of law, France
The ISU and WADA nominated Mr Jeffrey Mishkin, and Ms Valieva nominated Prof. Mathieu Maisonneuve. RUSADA being involved as Appellant in one procedure and as Respondent in the other two, it decided not to participate in the nomination process. The President of the Panel was appointed by the Deputy President of the Appeals Arbitration Division in accordance with the CAS Code.
The Panel and parties have established a detailed hearing timetable. The proceedings will open on Tuesday, 26 September 2023 with a short opening submission from each party, followed by the hearing of fact witnesses. On Wednesday, 27 September 2023, the Panel will hear expert witnesses and on Thursday, 28 September 2023, the Panel will hear the parties’ closing submissions and rebuttals. Should additional time be required, the Panel and parties have reserved Friday, 29 September 2023.
Following the hearing, the Panel will deliberate and prepare the Arbitral Award containing its decision. At this juncture, it is not possible to indicate when the final decision will be announced. The CAS Panel’s decision will be final and binding, with the exception of the parties’ right to file an appeal to the Swiss Federal Tribunal within 30 days on limited procedural grounds.
The hearing concerns the appeals filed individually by RUSADA, the ISU, and WADA against the decision issued by the RUSADA Disciplinary Anti-Doping Commission (RUSADA DADC) dated 14 December 2022 (the Challenged Decision), in which the Russian figure skater Kamila Valieva (the Athlete) was found to have committed an Anti-Doping Rule Violation (ADRV) for which she bore “no fault or negligence” and was not sanctioned with the exception of the disqualification of the results achieved on the date of the sample collection (25 December 2021).
RUSADA seeks a ruling from CAS setting aside the Challenged Decision and finding the Athlete to have committed an ADRV under the RUSADA Anti-Doping Rules (RUSADA ADR), and sanctioned with “the appropriate consequences (which may include or be limited to a reprimand) in respect of such ADRV pursuant to the RUSADA ADR”.
The ISU seeks a ruling from CAS sanctioning the Athlete with a four-year period of ineligibility or, subsidiarily, a two-year period of ineligibility, starting from 25 December 2021, as well as the disqualification of all results achieved by the Athlete during this period.
WADA seeks a ruling from CAS setting aside the Challenged Decision and finding the Athlete to have committed an ADRV under art. 4.1 and/or 4.2 of the RUSADA ADR, and sanctioned with a period of ineligibility of four years, as well as the disqualification of all competitive results obtained by the Athlete from and including 25 December 2021.
Ms Valieva seeks a ruling from CAS that it lacks jurisdiction over WADA, ISU and RUSADA claims, subsidiarily that no violation of the RUSADA ADR is proven and that she be re-established in the results obtained at the 2021 Russian Figure Skating Championship. In the alternative, she seeks a ruling that she bears no fault or negligence or, more subsidiarily, that the violation of the rules was not intentional, so that the period of ineligibility shall be at most two years and that no results shall be disqualified
In accordance with Article R52(5) of the CAS Code, the three appeals were consolidated and a common timetable was established for the filing of the parties’ written submissions. The exchange of written submissions, which was lengthened by extensions of time granted with the mutual agreement of the parties, has concluded.
On 24-25 August, the World Anti-Doping Agency’s (WADA’s) independent Compliance Review Committee (CRC) met in a hybrid fashion, for its second regular meeting this year, to discuss a range of important issues related to WADA’s World Anti-Doping Code (Code) Compliance Monitoring Program.
The CRC Chair, Mr. Henry Gourdji, who was accompanied by WADA Management in Montreal, lead discussions on the following matters:
-
New cases of Signatory non-compliance with the Code and International Standards, involving both legislation and Code Compliance Questionnaire (CCQ) cases; which, will be presented to WADA’s Executive Committee (ExCo) when they meet on 22 September 2023 (if the non-conformities discussed are not resolved by then);
-
The latest update on the reinstatement conditions imposed by the Court of Arbitration for Sport (CAS) in its award related to the case between WADA and the Russian Anti-Doping Agency (RUSADA);
-
An update on current non-compliant Signatories, including the Democratic People’s Republic of Korea (DPRK) and Gabon National Anti-Doping Organizations (NADOs) and the International Federation of Fitness and Bodybuilding (IFBB);
-
An update on the operations of Ukraine’s NADO and testing of Ukraine athletes. The Ukraine NADO has a suspended compliance case due to force majeure in relation to the ongoing Russian Federation invasion of Ukraine;
-
The latest on the amendments to the International Standard for Code Compliance by Signatories (ISCCS) following stakeholder consultation;
-
An update on the development and implementation of WADA’s Compliance Monitoring Program, including an update on anti-doping rules and legislation review, the CCQ and WADA’s Signatory audit program;
-
WADA’s progress on its Compliance Annual Plan for 2023 and risk management program.
The CRC also held two virtual in-camera sessions on 22 and 23 August to prepare, review and discuss documentation received for the meeting.
The CRC is responsible for providing independent advice, guidance and recommendations to WADA’s management and governing bodies on matters relating to Signatories' compliance with the Code.
The CRC Chair will report to WADA’s ExCo meeting on 22 September.
Global Summit 2024